- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: HER2 low
Total 24817 results
-
Vanderbilt UniversityForest LaboratoriesCompletedHypertension | Multiple System Atrophy | Pure Autonomic FailureUnited States
-
Strategic Science & Technologies, LLCCompleted
-
University of CambridgeBritish Heart FoundationUnknownEssential Hypertension | Hypertension, Resistant to Conventional TherapyUnited Kingdom
-
Hanmi Pharmaceutical Company LimitedCompleted
-
PfizerTerminatedPulmonary Arterial HypertensionSingapore
-
Sankyo Pharma GmbhCompletedRenal Impairment | Essential HypertensionGermany
-
Shanghai Jiao Tong University School of MedicineCompletedDiabetic Nephropathy | Type 2 Diabetes | Obese | Glucose Metabolism | Angiotensin II Type 1 Receptor Blockers
-
PfizerCompletedImpotenceNorway, United Kingdom
-
Southern Medical University, ChinaTerminatedDisease Progression | Proteinuria | Renal Insufficiency,Chronic | Dose-Response Relationship,Drug | ACE Inhibitor | Angiotensin II Type 1 Receptor BlockersChina
-
Massachusetts General HospitalCompleted
-
Peking University First HospitalNot yet recruiting
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruiting
-
Universitair Ziekenhuis BrusselKom Op Tegen Kanker; Agentschap voor Innovatie door Wetenschap en Technologie...RecruitingGastric Cancer | Colorectal Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Endometrial Cancer | Urothelial Carcinoma | Biliary Tract Cancer | Locally Advanced Breast Cancer | Cancer of Pancreas | Uterine Cancer | Salivary Gland Cancer | Metastatic Breast Carcinoma | Solid Tumor With Intermediate...Belgium
-
Karolinska University HospitalRecruitingBreast Cancer | Esophageal Neoplasms | HER2-positive Gastric Cancer | Gastric Neoplasms MalignantSweden
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedHER2 Positive MalignanciesUnited States
-
Shanghai Miracogen Inc.RecruitingLocally Advanced Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction CancerChina
-
University of Kansas Medical CenterCelgene CorporationCompleted
-
Beijing 302 HospitalRecruiting
-
First Affiliated Hospital of Zhejiang UniversityNot yet recruiting
-
Anne Arundel Health System Research InstituteGenentech, Inc.Unknown
-
Zhi YangWithdrawnGlioma | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung CancerChina
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
First People's Hospital of HangzhouMacera therapeuticsNot yet recruiting
-
Peking Union Medical College HospitalCompletedBreast CancerChina
-
Iksuda Therapeutics Ltd.RecruitingBreast Cancer | Gastric Cancer | Gastroesophageal-junction CancerAustralia
-
DualityBio Inc.RecruitingHER2-positive Advanced Solid TumorChina, United States, Australia, Puerto Rico
-
Jazz PharmaceuticalsBeiGene, Ltd.RecruitingGastroesophageal Adenocarcinoma | Esophageal Adenocarcinoma | Gastric NeoplasmsKorea, Republic of, Belgium, Japan, China, Netherlands, Spain, Germany, United Kingdom, Malaysia, Portugal, France, Italy, Australia, Taiwan, Turkey, Thailand, Argentina, Mexico, Ireland, Estonia, Serbia, Romania, Canada, Poland, Brazil, ... and more
-
Galena Biopharma, Inc.CompletedBreast Cancer With Low to Intermediate HER2 ExpressionUnited States, United Kingdom, France, Israel, Germany, Canada, Russian Federation, Romania, Bulgaria, Czech Republic, Hungary, Poland, Ukraine
-
Shanghai Miracogen Inc.RecruitingAdvanced or Metastatic Breast CancerChina
-
Pieris Pharmaceuticals, Inc.Active, not recruitingHER2-positive Gastric CancerUnited States, Korea, Republic of
-
PrecirixCompleted
-
su haichuanNot yet recruiting
-
Xijing HospitalNot yet recruitingHER2-positive Breast Cancer and Gastric Cancer
-
Bristol-Myers SquibbCompletedSolid Tumors That Overexpress HER2 (HER2 Positive)United States, Canada
-
Peking University Cancer Hospital & InstituteRecruitingHER2 Positive or Suspicious Positive TumorsChina
-
Alphamab (Australia) Co Pty Ltd.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsAustralia
-
Breast Cancer Trials, Australia and New ZealandNot yet recruitingBreast Cancer | Breast Cancer Female
-
Dorte NielsenTerminated
-
SystImmune Inc.RecruitingCervical Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Carcinoma | Biliary Tract CancerUnited States
-
University of SouthamptonAstraZeneca; Natera, Inc.RecruitingGastrooesophageal CancerUnited Kingdom
-
Amsterdam UMC, location VUmcAstraZenecaRecruitingBreast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric CancerNetherlands
-
Seagen Inc.Merck Sharp & Dohme LLC; RemeGen Co., Ltd.RecruitingUrothelial CarcinomaUnited States, Canada, Taiwan, Australia, Singapore
-
ArriVent BioPharma, Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768IUnited States, Australia, Spain, United Kingdom, France, China, Korea, Republic of, Canada, Japan, Netherlands, Italy
-
Shanghai Miracogen Inc.RecruitingBreast Cancer With Liver MetastasesChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingEsophageal Cancer | Esophageal AdenocarcinomaNetherlands
-
Shanghai Miracogen Inc.RecruitingAdvanced Solid TumorChina
-
Shanghai Miracogen Inc.RecruitingAdvanced or Metastatic Biliary Tract CancerChina
-
Shanghai PerHum Therapeutics Co., Ltd.Shanghai Zhongshan HospitalRecruitingSarcoma | Breast Cancer | Gastric Cancer | Ovarian Cancer | Solid TumorChina
-
AstraZenecaDaiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, TokyoRecruitingGastric CancerChina, Spain, Korea, Republic of, Canada, Italy, Poland, Japan, United Kingdom, Brazil, Taiwan, United States, Germany, Netherlands, Russian Federation
-
Herbert LyerlyRecruiting